2. Academic Validation
  3. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells

Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells

  • Neoplasia. 2019 Nov;21(11):1110-1120. doi: 10.1016/j.neo.2019.10.003.
C Otto 1,  S Schmidt 2,  C Kastner 3,  S Denk 2,  J Kettler 1,  N Müller 4,  C T Germer 5,  E Wolf 2,  P Gallant 2,  A Wiegering 6
Affiliations

Affiliations

  • 1 Experimental Visceral Surgery, Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery (Department of Surgery I), University Hospital Würzburg, Germany.
  • 2 University of Würzburg, Department of Biochemistry and Molecular Biology, Biocenter, Würzburg, Germany.
  • 3 University of Würzburg, Department of Biochemistry and Molecular Biology, Biocenter, Würzburg, Germany; Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery (Department of Surgery I), University Hospital Würzburg, Germany.
  • 4 Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany.
  • 5 Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery (Department of Surgery I), University Hospital Würzburg, Germany; University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
  • 6 University of Würzburg, Department of Biochemistry and Molecular Biology, Biocenter, Würzburg, Germany; Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery (Department of Surgery I), University Hospital Würzburg, Germany; University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany. Electronic address: Wiegering_A@ukw.de.
PMID: 31734632 DOI: 10.1016/j.neo.2019.10.003
Abstract

The transcriptional regulator BRD4 has been shown to be important for the expression of several oncogenes including MYC. Inhibiting of BRD4 has broad antiproliferative activity in different Cancer cell types. The small molecule JQ1 blocks the interaction of BRD4 with acetylated histones leading to transcriptional modulation. Depleting BRD4 via engineered bifunctional small molecules named PROTACs (proteolysis targeting chimeras) represents the next-generation approach to JQ1-mediated BRD4 inhibition. PROTACs trigger BRD4 for proteasomale degradation by recruiting E3 Ligases. The aim of this study was therefore to validate the importance of BRD4 as a relevant target in colorectal Cancer (CRC) cells and to compare the efficacy of BRD4 inhibition with BRD4 degradation on downregulating MYC expression. JQ1 induced a downregulation of both MYC mRNA and MYC protein associated with an antiproliferative phenotype in CRC cells. dBET1 and MZ1 induced degradation of BRD4 followed by a reduction in MYC expression and CRC cell proliferation. In SW480 cells, where dBET1 failed, we found significantly lower levels of the E3 ligase Cereblon, which is essential for dBET1-induced BRD4 degradation. To gain mechanistic insight into the unresponsiveness to dBET1, we generated dBET1-resistant LS174t cells and found a strong downregulation of Cereblon protein. These findings suggest that inhibition of BRD4 by JQ1 and degradation of BRD4 by dBET1 and MZ1 are powerful tools for reducing MYC expression and CRC cell proliferation. In addition, downregulation of Cereblon may be an important mechanism for developing dBET1 resistance, which can be evaded by incubating dBET1-resistant cells with JQ1 or MZ1.

Figures
Products